Course: Safety and Adverse Events Among Long-term Care Residents Receiving a Third COVID-19 mRNA Vaccine Booster Dose in Quebec
CME Credits: 1.00
Released: 2022-07-21
Booster doses of mRNA COVID-19 vaccines are administered worldwide to enhance antibody levels and immunity against Delta, Omicron, and emerging variants. Data on adverse events show a favorable safety profile, with similar reactogenicity for second and third doses. However, safety in older adults in long-term care (LTC) settings has not been well described., We examined adverse events following mRNA booster vaccination in LTC residents within the context of factors unique to the province of Quebec that may increase reactogenicity: extended interval between doses 1 and 2, heterologous vaccination, full dose mRNA-1273 (100 µg) booster, and high prevalence of previous COVID-19 infection.
Educational Objective
To identify the key insights or developments described in this article
View Full Course